Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.55 |
| ▸ | PI4KA | P42356 | 5/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | AHCY | P23526 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123842 | 1.00 | ADORA2A (0.59) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL29729351 | 1.00 | ADORA2A (0.59) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL8540979 | 0.79 | ADORA2A (0.56) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL13811638 | 0.78 | SRC (0.47) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL9192712 | 0.78 | SRC (0.44) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL4120696 | 0.78 | FGFR1 (0.45) | ADORA2AKDM4ELMNA | |
| SCHEMBL1798270 | 0.77 | ADORA2A (0.72) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4356218 | 0.76 | CDK1 (0.56) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL2560690 | 0.76 | KDM4E (0.50) | ADORA2AKDM4ELMNAADORA1PI4KA | |
| SCHEMBL2560694 | 0.76 | KDM4E (0.50) | ADORA2AKDM4ELMNAADORA1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332553-B2 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20070106041-A1 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20050159570-A1 | Functional monomers for molecular recognition and catalysis | MIP TECHNOLOGIES AB, RESEARCH PARK IDEON (SE) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106041-A1 | Functional monomers for molecular recognition and catalysis | PCNA, MUS81, PNMT | ADORA2A 4199/4885KDM4E 1566/4885LMNA 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.